In a landmark move, Baker McKenzie provided strategic counsel to VT5 Acquisition Company, a SIX-listed Swiss SPAC, on its acquisition of R&S International Holding. The compelling business combination, backed by an impressive 99% shareholder
Tags :Baker McKenzie
Baker McKenzie, with its teams in Singapore, Switzerland, and Japan, served as legal advisor to DBS Bank, UBS, and SBI Digital Asset Holdings in executing the world’s first cross-border repo and natively-issued digital bond
Luzerner Kantonalbank acted as arranger, agent, security agent and lender, along with other Swiss and Liechtenstein banks as lender in connection with their EUR 150 million financing of GarLa AcquiCo and its subsidiaries, GarLa Group. The
Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) has acquired the 68.0% of the shares in Swiss pharmaceutical company Osmopharm and has disinvested the 76.4% in Egyptian pharmaceutical manufacturer SPIMACO Misr for Pharmaceutical Industries. The Transaction, with
Baker McKenzie played a pivotal role in assisting IKEA AG with its latest venture, the acquisition of a development site in Riddes, located in the Valais canton of Switzerland. This collaboration marks a significant step
Helveteq, a Swiss issuer of ESG-transparent investment products, is launching a pioneering and unique solution for ecological and sustainable investments in gold. The company has issued and listed a new exchange traded product (ETP) on
Alessandro Celli, partner at Baker McKenzie Switzerland, speaks. “We have created a data-driven team.” by giuseppe salemme Alessandro Celli is a partner at Baker Mckenzie Switzerland and head of the Swiss Tmt practice group. He
Baker McKenzie has appointed its new Global Practice Group and Industry Group leaders, important areas of growth for the firm. All appointments will be effective from 1st July 2023. Regarding Switzerland, Intellectual Property partner Eva-Maria Strobel,
Baker McKenzie advised the shareholders of SpotMe Holding (“SpotMe”), a Lausanne-based company providing end-to-end event technology solutions, in connection with the sale of a majority stake to Swiss Post. SpotMe will continue to operate globally
Seamless Therapeutics, a German biotechnology firm, has successfully concluded a USD12.5 million Seed Financing, a university carve-out including equity financing, in-licensing of an innovative patent portfolio from Technische Universität Dresden and hiring of key
